Integrum presents health economic study of the OPRA[TM] Implant System showing long-term benefits for transfemoral amputees in the U.S.
Mölndal, Sweden, November 17, 2022 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announced that the initial cost-effectiveness analysis of the OPRA[TM ]Implant System focused on US healthcare data was presented at the 99[th] Annual ACRM Annual Conference in Chicago. The study concluded that for active transfemoral amputees, the use of the OPRA[TM] Implant System is a cost-effective alternative to a socket prosthesis.The “Cost-effectiveness analysis of osseointegrated prostheses for transfemoral amputation” poster was presented by Jeff Voigt, MBA, MPH, the lead author,